- Home
- GOSS vs INKT Comparison
GOSS vs INKT Comparison
Compare GOSS & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOSS | INKT |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | 162 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.6M | 59.4M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GOSS | INKT |
|---|---|---|
| Price | $10.56 | $12.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 2 |
| Target Price | $4.19 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 8.2M | 11.2K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,471,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $201.64 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.11 | $8.48 |
| 52 Week High | $12.52 | $16.00 |
Technical Indicators
Market Signals| Indicator | GOSS | INKT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.